Cell-penetrating antibodies could crack 'undruggable' cancer mutation

DNA
RAS mutations are present in 30% of all cancers, but occur disproportionately in pancreatic cancer.

RAS mutations have long been an attractive target in cancer treatment, but scientists have struggled to find a drug that safely combats their effects. A South Korean team has developed a way to block RAS activity in tumor cells, thus promoting anti-tumor activity.

RAS mutations, which show up in about 30% of all cancers, activate RAS proteins. Tumors that contain these aberrations tend to be aggressive and resist treatments. And while scientists have worked on this target for decades, it is still thought of as “undruggable.”

Scientists at Ajou University and Orum Therapeutics devised a monoclonal antibody, RT11-i, which targets the RAS protein in cells. After it penetrates cells, it selectively binds to activated RAS, stopping it from interacting with effector proteins and setting off a cascade of tumor-promoting signaling.

WEBINAR

Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

In mice with tumors containing a RAS mutation, the treatment had “measurable antitumor activity,” according to a statement. The team also administered RT11-i alongside the EGFR inhibitor cetumixab to mice with treatment-resistant colorectal cancer. The combo unlocked the resistance, suggesting a possible treatment for patients with advanced colon cancer and RAS mutations, said principal investigator and Orum cofounder Yong Sung Kim.

"As an anti-cancer therapy, our cell penetrating antibodies are easy to produce, allow for systemic administration that is well tolerated, and have desirable pharmacological properties," said Sung Joo Lee, Ph.D., Co-founder and CEO of Orum Therapeutics. "We believe this could be a very important first-in-class therapeutic for hard-to-treat pancreatic, colon and non-small cell lung cancers." The work is published in Nature Communications.

Another way to target activated RAS is to use a synthetic binding protein, also called a monobody. A team from the University of Illinois at Chicago found that its NS1 monobody binds to a spot on the RAS protein molecule, which stops it from joining with an identical molecule to form a pair. This blocks the oncogenic activity of two out of three RAS proteins.

Successfully blocking RAS activity could be important for often deadly pancreatic cancers, 95% of which have RAS mutations, as well as for colorectal cancer (45%), lung cancer (35%) and melanoma, the deadliest of the skin cancers.

Suggested Articles

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

​​​​​​​The week’s biotech news included a map of the human lung that could aid asthma drug development and a compound that thwarts rhinoviruses like colds.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.